Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

MedWell Laboratories

Out of Business LATEST DEAL TYPE

Developer of non-steroidal anti-inflammatory drugs. The company develops non-steroidal anti-inflammatory drugs for treatment of mild to moderate chronic inflammatory disorders. It develops drug which are effective and safe due to the mechanism of action as cyclooxygenase 2 (COX-2) and 5-Lipoxygenase (5-LOX) enzymes dual inhibition.

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • Nazareth Industrial Area
  • P.O. Box 2252
  • Nazareth 16000
  • Israel
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore MedWell Laboratories’s full profile, request a free trial.

MedWell Laboratories Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Oct-2017 Completed Out of Business
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

MedWell Laboratories Executive Team (2)

Name Title Board
Michal Olshansky Chief Executive Officer
Taher Nassar Ph.D Co-Founder, Inventor, Board Member & Chief Scientist

MedWell Laboratories Board Members (3)

Name Representing Role Since Contact
Nasri Said MedWell Laboratories Chairman 000 0000
Oren Fuerst Ph.D Self Board Member 000 0000
Sheila Oren MD Self Board Member 000 0000